Literature DB >> 8234173

Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of Macaca nemestrina.

A Lopez-Anaya1, J D Unadkat, D F Calkins, A L Smith.   

Abstract

The brain tissue is an important target for anti-HIV drug therapy. Since the permeability of the blood-brain and blood-cerebrospinal fluid (CSF) barriers may differ between neonates and adults, we have determined the effect of age on the distribution of zidovudine (ZDV or azidothymidine) into the CSF in the macaque (M. nemestrina). Five newborn macaques were administered ZDV (iv bolus, 5 mg/kg) at various ages (2 days to 4 months). Both CSF (cisternal) and venous blood samples were obtained at approximately 60 and 90 min after drug administration. In another series of experiments, adult female macaques received ZDV as either an iv bolus (5 and 10 mg/kg) or an infusion for at least 12 hr. CSF (lumbar) and venous blood samples were obtained at approximately 60 and 90 min after iv bolus and at more than 12 hr after iv infusion. ZDV concentration in the CSF and the plasma samples was determined by high-performance liquid chromatography. The CSF/plasma concentration ratio of ZDV in the newborn and adult macaques, after iv bolus administration, was independent of time. In addition, no significant (P > 0.05) difference was observed in the pooled iv bolus ZDV CSF/plasma concentration ratio between the adult group (0.236 +/- 0.058) and the newborns (0.213 +/- 0.039). Moreover, the ZDV CSF/plasma concentration ratio in the adults and the newborns, after iv bolus administration, was found not to be significantly (P > 0.05) different from the ratio obtained at steady state in the adults (0.224 +/- 0.094). These data indicate that the distribution of ZDV into the CSF in macaque neonates and adults is similar.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234173     DOI: 10.1023/a:1018977915364

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

Review 1.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

2.  Pediatric acquired immunodeficiency syndrome. Neurologic syndromes.

Authors:  A L Belman; G Diamond; D Dickson; D Horoupian; J Llena; G Lantos; A Rubinstein
Journal:  Am J Dis Child       Date:  1988-01

3.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.

Authors:  K M Butler; R N Husson; F M Balis; P Brouwers; J Eddy; D el-Amin; J Gress; M Hawkins; P Jarosinski; H Moss
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

4.  Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate.

Authors:  A Lopez-Anaya; J D Unadkat; L A Schumann; A L Smith
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  Development of a "blood-brain barrier" to methadone in the newborn rat.

Authors:  M A Peters
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

6.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

7.  Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.

Authors:  P A Pizzo; J Eddy; J Falloon; F M Balis; R F Murphy; H Moss; P Wolters; P Brouwers; P Jarosinski; M Rubin
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

8.  Pharmacokinetics of zidovudine (azidothymidine). III. Effect of pregnancy.

Authors:  A Lopez-Anaya; J D Unadkat; L A Schumann; A L Smith
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

9.  Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers.

Authors:  M A Hedaya; W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

10.  Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.

Authors:  R Yarchoan; J M Pluda; R V Thomas; H Mitsuya; P Brouwers; K M Wyvill; N Hartman; D G Johns; S Broder
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

View more
  4 in total

Review 1.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

2.  Pharmacokinetics of dideoxyinosine in neonatal pigtailed macaques.

Authors:  C M Pereira; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

3.  Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.

Authors:  T Tuntland; R J Ravasco; S al-Habet; J D Unadkat
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

4.  Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina).

Authors:  R D Keller; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.